AI Article Synopsis
- Ebola virus infection leads to severe haemorrhagic fever and has a high mortality rate, making it a significant health threat and classified as a category A pathogen.
- The development of vaccines, particularly through plant-based methods, has garnered interest as a promising approach to combat the Ebola virus.
- Recent advancements in using plants for producing vaccines and monoclonal antibodies are aimed at addressing public health concerns related to Ebola virus disease.
Article Abstract
Ebola virus infection results in the fast onset of severe acute haemorrhagic fever with high mortality. The Ebola virus is labelled as a category A pathogen. Vaccines against the Ebola virus (EBOV) are essential for everyone, and an expansion in the arena of vaccine synthesis; especially, plant-based vaccine development has drawn attention. To express the heterologous protein for plant-based vectors, both RNA and DNA viruses have been adapted. Among the different approaches of plant-based vaccine technologies, the agroinfiltration method, which was initially established to investigate plant-virus interactions, has been considered an effective method to produce monoclonal antibodies against EBOV. The effectiveness of plants as bioreactors of vaccine/monoclonal antibodies development could be well-thought-out to attend the obligatory mandate. The review confers recent progress in the production of plant-based vaccines and antibody treatments against the Ebola virus disease, thereby alleviating public health alarms associated with EBOV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.coph.2021.08.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccination Strategies for Ebola in the Democratic Republic of Congo: The WHO-Ebola Modeling Collaboration.
Int J Infect Dis
January 2025
Department of Biostatistics, University of Florida, Gainesville, USA. Electronic address:
Objectives: Assess the effectiveness of ring vaccination in controlling an Ebola virus outbreak in the Democratic Republic of Congo.
Methods: This analysis focuses on two areas of the Democratic Republic of Congo, Beni and Butembo/Katwa, which were affected during the 2018-2020 Ebola outbreak. To simulate Ebola virus transmission, we used a spatially explicit agent-based model with households, health care facilities, and Ebola treatment units.
Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates.
Nat Med
January 2025
Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or approved treatments exist for MARV infection, distinguishing it from related viruses like Ebola. Our research demonstrates that the oral drug obeldesivir (ODV), a nucleoside analog prodrug, shows promising antiviral activity against filoviruses in vitro and offers significant protection in animal models.
View Article and Find Full Text PDFDiscovery of anti-Ebola virus multi-target inhibitors from traditional Chinese medicine database using molecular screening, biophysical investigation, and binding free energy calculations.
J Infect Public Health
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. Electronic address:
Article Synopsis
- Ebola virus (EBOV) is a highly deadly RNA virus that currently lacks effective treatments or vaccines, necessitating the urgent need for new therapeutic solutions.
- In this study, researchers used in silico methods to evaluate natural products from traditional Chinese medicine against four critical EBOV proteins, employing molecular docking to assess their potential effectiveness.
- The findings identified eight promising compounds with strong inhibitory effects on EBOV proteins, indicating their potential as antiviral agents due to their favorable interaction with protein residues and acceptable pharmacokinetic profiles.
Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo.
Immunology
January 2025
The Key Laboratory for Human Disease Gene Study of Sichuan Province, Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Many virus species, including Ebola virus, Marburg virus, SARS-CoV-2, dengue virus (DENV) and Zika virus (ZIKV), exploit CD209 and CD209L as alternative or attachment receptors for viral cis- or trans-infection. Thus, CD209 and CD209L may be critical targets for the development of therapeutic monoclonal blocking antibody drugs to disrupt the infection process caused by multiple viruses. Here, we produced a human chimeric monoclonal blocking antibody that simultaneously blocks CD209 and CD209L, namely 7-H7-B1.
View Article and Find Full Text PDFIs there sufficient evidence to inform personal protective equipment choices for healthcare workers caring for patients with viral hemorrhagic fevers?
Can Commun Dis Rep
January 2025
Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, Ottawa, ON.
Background: Ugandan health authorities declared an outbreak of Ebola disease (EBOD), caused by the Sudan virus, in September 2022. A rapid review was conducted to update the Public Health Agency of Canada's guidelines for infection prevention and control measures for EBOD in healthcare settings to prepare for potential introduction of cases.
Objective: Summarize the available evidence on personal protective equipment (PPE) use by healthcare workers (HCWs) to prevent exposure to and transmission of viral hemorrhagic fevers (VHFs), including Ebola virus.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!